about
A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activationEnhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsModulation of Immune Functions by FoodsSustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.Role of NK, NKT cells and macrophages in liver transplantationCCL21 Chemokine Therapy for Lung Cancer.Invariant NKT cells sustain specific B cell responses and memory.Non-classical natural killer T cells modulate plasmid DNA vaccine antigen expression and vaccine-elicited immune responses by MCP-1 secretion after interaction with a beta2-microglobulin-independent CD1d.NKG2A inhibits invariant NKT cell activation in hepatic injury.Galactosylsphingamides: new α-GalCer analogues to probe the F'-pocket of CD1d.NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas.Designing vaccines based on biology of human dendritic cell subsetsAntigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potencyActivation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cellsDendritic cell subsets in health and disease.Pentachlorophenol and cancer risk: focusing the lens on specific chlorophenols and contaminants.Differential antitumor immunity mediated by NKT cell subsets in vivoActivation of natural killer T cells by alpha-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi.NKT cells: potential targets for autoimmune disease therapy?IL-15 availability conditions homeostasis of peripheral natural killer T cells.Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines.Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.The CD1 family and T cell recognition of lipid antigens.Regulatory T cells in the control of transplantation tolerance and autoimmunity.Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences.GM-CSF-secreting melanoma vaccines.Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivoAlpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Bone marrow and the control of immunity.Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disordersParallels and distinctions between T and NKT cell development in the thymus.Genetic control of NKT cell numbers.Natural killer T cells as targets for immunotherapy of autoimmune diseases.Regulation of antitumour immunity by CD1d-restricted NKT cells.NKT cells and viral immunity.IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2.
P2860
Q21260433-A3A91B0B-BDF8-4B47-BC43-84044156CD34Q24685895-E2E69958-C511-4E13-8AD2-97B044E5A0DFQ24808820-251CA1B4-A437-4786-B374-7D4A422A1C44Q25255724-02CAB176-5E90-4368-949E-B39743CC86D0Q26741191-F53106EE-005A-407B-9598-4B7166DCFB90Q28248811-1966CCEA-F5A0-481F-B22B-BE403425B705Q30479030-44CBABF3-F9F8-47E5-B233-E5ECDDF3AE62Q33553298-CCC2AC87-B866-4E7A-B9C5-7158593B81B8Q33739557-61CBE8FE-B8B7-4CAF-8BA8-9C3E651C1497Q33842953-ACA03B9C-D215-461D-BAA0-696FAF7E1897Q34078681-CC00752B-F248-4EA5-A4B0-A0C5F068B693Q34255022-ECA37310-3535-4816-AA71-7AD28D44D98BQ34289152-F18E53F8-F912-4D55-B81C-708B0F650904Q34338958-9E8C6BD8-AE52-42FF-8C62-BD37015E2758Q34467874-F3B2850A-17FC-45CC-AA2E-234684AC29FCQ34582889-821B4305-6D78-40BB-8761-9D3A75CA4DC7Q34595658-223F8438-221E-4DF9-AD03-E43A432268FEQ34603019-E37CBD79-89EB-4AE6-8EC5-1D3795E0B6B7Q34714252-3A03F3EF-891E-4D9A-B9ED-6C62033E5F71Q34764715-8B18A2AA-BBD2-42A0-97AF-8DA27F9251BDQ34807830-6CDF3119-FC91-4E8E-A89D-E09C576E58AFQ35005903-73F5B808-C870-4C8F-81E0-0DBEA0284567Q35005930-7BFF106D-BA50-42A0-A4C8-61580EB1832CQ35005940-E6B2D8BF-A69C-4140-853C-06EC67238EA9Q35030902-A00ABD19-3A14-4909-B49D-281D8E65E77DQ35129539-A17753B9-E945-4422-98B9-794CED20068AQ35131643-CFF5CF7A-2A42-4D8A-8E4D-1F7C401507E1Q35146599-9E6C5747-6310-48F0-8D7A-9BF1112459E9Q35168204-EA1100A5-8250-43C3-A2FD-38C850AE2AC1Q35234774-D9DB1F25-7268-4079-A3A1-0BC172E9D49DQ35567765-14D39B3C-E463-485A-A348-BBC564BD681CQ35653129-B5E79438-C855-4A8E-88C5-F5BBCCF0F972Q35713347-EAF4EFA9-9CD6-43D8-BECB-B5567BD9916EQ35761273-93AC6F4C-38AD-4C25-B1EA-9137DF33D625Q35798134-70DF7012-36A1-455F-98F4-5937DD590100Q35798141-C9811C77-DA19-4957-BCA6-83C67E8F6BC3Q35798168-EAC097A1-8444-4815-91C3-4F7AD94B1574Q35798173-860C4D23-E957-468B-8E63-077C3B506AFDQ35798179-A4155AB6-DEA6-4C0A-B52A-613738CB4893Q35847866-5BEC4E70-6CF2-4B03-96FE-485B5411F9CC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
NKT cells - conductors of tumor immunity?
@ast
NKT cells - conductors of tumor immunity?
@en
NKT cells - conductors of tumor immunity?
@nl
type
label
NKT cells - conductors of tumor immunity?
@ast
NKT cells - conductors of tumor immunity?
@en
NKT cells - conductors of tumor immunity?
@nl
altLabel
NKT cells — conductors of tumor immunity?
@en
prefLabel
NKT cells - conductors of tumor immunity?
@ast
NKT cells - conductors of tumor immunity?
@en
NKT cells - conductors of tumor immunity?
@nl
P2093
P50
P1476
NKT cells - conductors of tumor immunity?
@en
P2093
Kazuyoshi Takeda
Nadine Y Crowe
Yoshihiro Hayakawa
P304
P356
10.1016/S0952-7915(02)00316-3
P577
2002-04-01T00:00:00Z